Wisevoter
U.S.

FDA Accepted Orvida Pharma Drug Into Rare Disease Program

The FDA will provide guidance on data requirements for ontivatrep, an oral therapy for Olmsted syndrome.

Updated on Oct. 14, 2026 in Biotech

Isometric editorial illustration of laboratory beakers and a pipette, representing the regulatory review process for rare disease medical treatments.
The FDA has accepted Orvida Pharma's ontivatrep into the Rare Disease Evidence Principles process, setting a framework for future review. AI Illustration. Upload story photo >

Live Poll

Do you trust that pharmaceutical firms are sufficiently prioritizing the development of treatments for rare diseases?

The FDA has accepted Orvida Pharma's KM-023 into the Rare Disease Evidence Principles (RDEP) process. This engagement allows the company to coordinate with regulatory teams on the specific evidence required for the potential approval of ontivatrep.

Why it matters

Olmsted syndrome is a genetic skin disorder with no currently approved therapies, representing a significant unmet medical need. The RDEP process aims to accelerate review timelines by providing clarity on the necessary data for rare disease treatments.

Orvida Pharma completed a Phase 1a safety study for ontivatrep involving 30 healthy volunteers in April 2026. The company is currently testing the oral investigational therapy in a Phase 1b clinical trial across the United States and Europe.

The players

FDA

The Food and Drug Administration is the federal agency responsible for regulating food and drug safety in the United States.

Orvida Pharma

Orvida Pharma is a pharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing treatments for rare conditions.

The details

Through the RDEP process, sponsors collaborate with FDA reviewers to define necessary benchmarks for safety and effectiveness. Evidence accepted for such reviews may include natural history studies, biomarker data, case reports, or nonclinical models.

Timeline

  1. April 2026: Orvida reported Phase 1a safety data.

  2. October 14, 2026: FDA accepted KM-023 into the RDEP process.

  3. November 9-11, 2026: Company presentation at BIO-Europe 2026.

  4. November 16-19, 2026: Company participation in Jefferies Global Healthcare Conference.

  5. Year-end 2026: Topline Phase 1b results are expected.

The Tech Race

The Rare Disease Evidence Principles process represents a strategic evolution in how the FDA handles therapies for conditions with limited patient populations. By enabling early, iterative dialogue between sponsors and regulators, this program aims to replace traditional bottleneck-heavy approval pathways with more agile evidence-gathering protocols.

For patients suffering from Olmsted syndrome, this development signifies a potential step toward the first-ever approved treatment for their condition. The RDEP engagement reduces uncertainty for developers, which can influence the speed at which specialized therapies reach the market.

The takeaway

The RDEP process creates a structured pathway for addressing the lack of treatments for rare diseases like Olmsted syndrome. This regulatory progress is a critical component for biotech firms seeking to demonstrate safety and efficacy in highly specialized patient cohorts.

What happens next

Topline results from the Phase 1b clinical trial are expected at year-end 2026.

Further reading

Learn more about the latest innovations in Biotech.

Source note: This article includes information reported by The Manila times.

Live Poll

Do you trust that pharmaceutical firms are sufficiently prioritizing the development of treatments for rare diseases?